Histopathology 2022 August 25 [Link] Andrew Churg, Julia R Naso Abstract Separation of mesothelioma from metastatic carcinoma requires immunohistochemical support, with small batteries of stains recommended as a starting-point, but these numbers commonly expand to 10, 12 or more stains, a process that is not only expensive but frequently generates anomalous or confounding results, leading…

Read More

European Journal of Cancer 2022 July 11 [Link] Daphne W Dumoulin, Luca Cantini, Robin Cornelissen, Madelief Vink, Larissa Klaase, Kick Sloof, Nura Tebayna, Joanne M Mankor, Sara J Baart, Rudi Hendriks, Anne-Marie C Dingemans, Marcella Willemsen, Joachim G J V Aerts Abstract Purpose: Lurbinectedin is a promising new drug being investigated in pre-treated patients with…

Read More

American Journal of Industrial Medicine 2022 June 1 [Link] Dirk Taeger, Katharina Wichert, Martin Lehnert, Swaantje Casjens, Beate Pesch, Daniel G Weber, Thomas Brüning, Georg Johnen, Thomas Behrens Abstract Background: Asbestos causes mesothelioma and lung cancer. In the European Union, asbestos was banned in 2005, but it is still in use in many other countries.…

Read More

Frontiers in Oncology 2022 May 6 [Link] Eline Janssens, Zoë Mol, Lore Vandermeersch, Sabrina Lagniau, Karim Y Vermaelen, Jan P van Meerbeeck, Christophe Walgraeve, Elly Marcq, Kevin Lamote Abstract Introduction: Malignant pleural mesothelioma (MPM) is a lethal cancer for which early-stage diagnosis remains a major challenge. Volatile organic compounds (VOCs) in breath proved to be…

Read More

Scientific Reports 2022 May 23 [Link] Misa Ichikawa, Naomi Muramatsu, Wataru Matsunaga, Takahiro Ishikawa, Tomoyuki Okuda, Hirokazu Okamoto, Akinobu Gotoh Abstract Gene therapy using vectors has attracted attention in recent years for the treatment of cancers caused by gene mutations. Besides, new treatments are imperative for lung cancer, including non-small cell lung cancer (NSCLC) and…

Read More

Medicine 2022 January 7 [Link] Takeshi Saraya, Kosuke Ohkuma, Masachika Fujiwara, Haruyuki Ishii Abstract Malignant mesothelioma (MM) is difficult to diagnose because of the lack of parenchymal opacities, often revealing minimal or absent pleural thickening. Furthermore, pleural effusion has diverse differential diagnoses, including malignancies, infections, as well as collagen vascular and other benign diseases. In…

Read More

Biomedical Chromatography 2021 November 5 [Link] Eleonora W J van Ewijk-Beneken Kolmer, Marga J A Teulen, Rene J Boosman, Nikki de Rouw, Jacobus A Burgers, Rob Ter Heine Abstract Pemetrexed is an antifolate drug approved for the treatment of non-small-cell lung cancer and mesothelioma. Assessing pemetrexed pharmacokinetics after administration of a microdose (100 μg) may…

Read More

International Journal of Molecular Sciences 2021 July 10 [Link] Li Yuan, Boshu Sun, Liangliang Xu, Limin Chen, Wenbin Ou Abstract SET domain bifurcated 1 (SETDB1) is a histone H3 lysine 9 (H3K9) methyltransferase that exerts important effects on epigenetic gene regulation. SETDB1 complexes (SETDB1-KRAB-KAP1, SETDB1-DNMT3A, SETDB1-PML, SETDB1-ATF7IP-MBD1) play crucial roles in the processes of histone…

Read More

Frontiers in Oncology 2021 June 15 [Link] Alice Faversani, Chiara Favero, Laura Dioni, Angela Cecilia Pesatori, Valentina Bollati, Matteo Montoli, Valeria Musso, Andrea Terrasi, Nicola Fusco, Mario Nosotti, Valentina Vaira, Alessandro Palleschi Abstract Background: Despite significant improvement in screening programs for cancers of the respiratory district, especially in at-risk subjects, early disease detection is still…

Read More

Translational Lung Cancer Research 2021 April [Link] Gerard G Hanna, Thomas John, David L Ball Abstract Malignant pleural mesothelioma is an uncommon thoracic cancer with a relatively poor outcome, which has only seen modest improvements when compared to non-small cell lung cancer. The mainstays of treatment have been surgery and systemic therapy, with radiation reserved…

Read More